A Gambineri1, E Scarano2, P Rucci3, A Perri2, F Tamburrino2, P Altieri4, F Corzani4, C Cecchetti4, P Dionese4, E Belardinelli4, D Ibarra-Gasparini4, S Menabò5, V Vicennati4, A Repaci4, G di Dalmazi4, C Pelusi4, G Zavatta4, A Virdi6, I Neri6, F Fanelli4, L Mazzanti2, U Pagotto4. 1. Unit of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Massarenti 9, 40138, Bologna, Italy. alessandra.gambiner3@unibo.it. 2. Pediatric Endocrinology and Rare Disease Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. 3. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. 4. Unit of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Via Massarenti 9, 40138, Bologna, Italy. 5. Genetic Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. 6. Division of Dermatology, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Abstract
PURPOSE: Many questions concerning Turner syndrome (TS) remain unresolved, such as the long-term complications and, therefore, the optimal care setting for adults. The primary aim of this long-term cohort study was to estimate the incidence of comorbid conditions along the life course. METHODS: A total of 160 Italian patients with TS diagnosed from 1967 to 2010 were regularly and structurally monitored from the diagnosis to December 2019 at the University Hospital of Bologna using a structured multidisciplinary monitoring protocol. RESULTS: The study cohort was followed up for a median of 27 years (IQR 12-42). Autoimmune diseases were the comorbid condition with the highest incidence (61.2%), followed by osteoporosis and hypertension (23.8%), type 2 diabetes (16.2%) and tumours (15.1%). Median age of onset ranged from 22 years for autoimmune diseases to 39 years for type 2 diabetes. Malignant tumours were the most prominent type of neoplasm, with a cumulative incidence of 11.9%. Papillary thyroid carcinoma was the most common form of cancer, followed by skin cancer and cancer of the central nervous system. Only one major cardiovascular event (acute aortic dissection) was observed during follow-up. No cases of ischaemic heart disease, heart failure, stroke or death were recorded. CONCLUSIONS: This cohort study confirms the need for continuous, structured and multidisciplinary lifelong monitoring of TS, thus ensuring the early diagnosis of important comorbid conditions, including cancer, and their appropriate and timely treatment. In addition, these data highlight the need for the increased surveillance of specific types of cancer in TS, including thyroid carcinoma.
PURPOSE: Many questions concerning Turner syndrome (TS) remain unresolved, such as the long-term complications and, therefore, the optimal care setting for adults. The primary aim of this long-term cohort study was to estimate the incidence of comorbid conditions along the life course. METHODS: A total of 160 Italian patients with TS diagnosed from 1967 to 2010 were regularly and structurally monitored from the diagnosis to December 2019 at the University Hospital of Bologna using a structured multidisciplinary monitoring protocol. RESULTS: The study cohort was followed up for a median of 27 years (IQR 12-42). Autoimmune diseases were the comorbid condition with the highest incidence (61.2%), followed by osteoporosis and hypertension (23.8%), type 2 diabetes (16.2%) and tumours (15.1%). Median age of onset ranged from 22 years for autoimmune diseases to 39 years for type 2 diabetes. Malignant tumours were the most prominent type of neoplasm, with a cumulative incidence of 11.9%. Papillary thyroid carcinoma was the most common form of cancer, followed by skin cancer and cancer of the central nervous system. Only one major cardiovascular event (acute aortic dissection) was observed during follow-up. No cases of ischaemic heart disease, heart failure, stroke or death were recorded. CONCLUSIONS: This cohort study confirms the need for continuous, structured and multidisciplinary lifelong monitoring of TS, thus ensuring the early diagnosis of important comorbid conditions, including cancer, and their appropriate and timely treatment. In addition, these data highlight the need for the increased surveillance of specific types of cancer in TS, including thyroid carcinoma.
Authors: Kim Freriks; Janneke Timmermans; Catharina C M Beerendonk; Chris M Verhaak; Romana T Netea-Maier; Barto J Otten; Didi D M Braat; Dominique F C M Smeets; Dirk H P M Kunst; Ad R M M Hermus; Henri J L M Timmers Journal: J Clin Endocrinol Metab Date: 2011-07-13 Impact factor: 5.958
Authors: Doreen M Rabi; Kerry A McBrien; Ruth Sapir-Pichhadze; Meranda Nakhla; Sofia B Ahmed; Sandra M Dumanski; Sonia Butalia; Alexander A Leung; Kevin C Harris; Lyne Cloutier; Kelly B Zarnke; Marcel Ruzicka; Swapnil Hiremath; Ross D Feldman; Sheldon W Tobe; Tavis S Campbell; Simon L Bacon; Kara A Nerenberg; George K Dresser; Anne Fournier; Ellen Burgess; Patrice Lindsay; Simon W Rabkin; Ally P H Prebtani; Steven Grover; George Honos; Jeffrey E Alfonsi; JoAnne Arcand; François Audibert; Geneviève Benoit; Jesse Bittman; Peter Bolli; Anne-Marie Côté; Janis Dionne; Andrew Don-Wauchope; Cedric Edwards; Tabassum Firoz; Jonathan Y Gabor; Richard E Gilbert; Jean C Grégoire; Steven E Gryn; Milan Gupta; Fady Hannah-Shmouni; Robert A Hegele; Robert J Herman; Michael D Hill; Jonathan G Howlett; Gregory L Hundemer; Charlotte Jones; Janusz Kaczorowski; Nadia A Khan; Laura M Kuyper; Maxime Lamarre-Cliche; Kim L Lavoie; Lawrence A Leiter; Richard Lewanczuk; Alexander G Logan; Laura A Magee; Birinder K Mangat; Philip A McFarlane; Donna McLean; Andre Michaud; Alain Milot; Gordon W Moe; S Brian Penner; Andrew Pipe; Alexandre Y Poppe; Evelyne Rey; Michael Roerecke; Ernesto L Schiffrin; Peter Selby; Mike Sharma; Ashkan Shoamanesh; Praveena Sivapalan; Raymond R Townsend; Karen Tran; Luc Trudeau; Ross T Tsuyuki; Michel Vallée; Vincent Woo; Alan D Bell; Stella S Daskalopoulou Journal: Can J Cardiol Date: 2020-05 Impact factor: 5.223
Authors: Minouk J Schoemaker; Anthony J Swerdlow; Craig D Higgins; Alan F Wright; Patricia A Jacobs Journal: Lancet Oncol Date: 2008-02-20 Impact factor: 41.316
Authors: Margaret M Fuchs; Christine Attenhofer Jost; Dusica Babovic-Vuksanovic; Heidi M Connolly; Alexander Egbe Journal: J Am Heart Assoc Date: 2019-06-04 Impact factor: 5.501